Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Case Report

A Case of Wild-type Cardiac Transthyretin Amyloidosis Diagnosed by Non-invasive Methods

Author(s): David Andrés Lizarazo Ortega*, Bibiana Pinzón Valderrama, Gina González-Robledo and Patricia Bernal Trujillo

Volume 19, Issue 4, 2023

Published on: 26 August, 2022

Article ID: e100622205814 Pages: 5

DOI: 10.2174/1573405618666220610091446

Price: $65

conference banner
Abstract

Introduction: Transthyretin amyloid cardiomyopathy was considered a rare pathology. However, recent studies show a significant prevalence in patients with degenerative aortic stenosis and heart failure with preserved ejection fraction.

Case Presentation: An 85-year-old woman presented with a four-month history of pain in the rib cage with a history of diffuse large B-cell lymphoma of the oral cavity, essential thrombocytosis and dyslipidemia. She had no significant family history. A transthoracic echocardiogram showed degenerative aortic stenosis and normal systolic function with preserved left ventricular ejection fraction of 70%. Bone-avid tracer cardiac scintigraphy with technetium-99m-labeled hydroxymethylene diphosphonate with SPECT-CT documented grade two myocardial uptake according to the Perugini scale. MRI evidenced late patchy enhancement in the myocardium associated with diffuse subendocardial enhancement. Laboratory tests showed the absence of mutation in the transthyretin (TTR) gene, serum and urine immunofixation electrophoresis (IFE) negative for monoclonal protein and serum-free light chain (sFLC) assay with a normal kappa/lambda (K/L) ratio. All these findings were compatible with a non-invasive diagnosis of wild-type cardiac amyloidosis.

Conclusion: The accepted criteria for the definitive non-invasive diagnosis of amyloid cardiomyopathy are based on myocardial uptake by scintigraphy (with SPECT), serum and urine immunofixation electrophoresis, serum-free light chain assay and suggestive findings on echocardiography and/or MRI. Genetic testing should differentiate between ATTRv (v for variant) and ATTRwt (wt for wild type) forms.

Keywords: Amyloidosis, transthyretin-related amyloid fibril protein, human immunoglobulin light-chain amyloidosis, nuclear medicine, magnetic resonance imaging, cardiomyopathy.

Graphical Abstract
[1]
Ash S, Shorer E, Ramgobin D, et al. Cardiac amyloidosis-A review of current literature for the practicing physician. Clin Cardiol 2021; 44(3): 322-31.
[http://dx.doi.org/10.1002/clc.23572] [PMID: 33595871]
[2]
Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: Evolving diagnosis and management: A scientific statement from the American heart association. Circulation 2020; 142(1): e7-e22.
[http://dx.doi.org/10.1161/CIR.0000000000000792] [PMID: 32476490]
[3]
Garcia-Pavia P, Rapezzi C, Adler Y, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2021; 42(16): 1554-68.
[http://dx.doi.org/10.1093/eurheartj/ehab072] [PMID: 33825853]
[4]
Witteles RM, Bokhari S, Damy T, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. JACC Heart Fail 2019; 7(8): 709-16.
[http://dx.doi.org/10.1016/j.jchf.2019.04.010] [PMID: 31302046]
[5]
Perugini E, Guidalotti PL, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005; 46(6): 1076-84.
[http://dx.doi.org/10.1016/j.jacc.2005.05.073] [PMID: 16168294]
[6]
Dorbala S, Cuddy S, Falk RH. How to image cardiac amyloidosis: A practical approach. JACC Cardiovasc Imaging 2020; 13(6): 1368-83.
[http://dx.doi.org/10.1016/j.jcmg.2019.07.015] [PMID: 31607664]
[7]
Hanna M, Ruberg FL, Maurer MS, et al. Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC Review Topic of the Week. J Am Coll Cardiol 2020; 75(22): 2851-62.
[http://dx.doi.org/10.1016/j.jacc.2020.04.022] [PMID: 32498813]
[8]
Mohamed-Salem L, Santos-Mateo JJ, Sanchez-Serna J, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol 2018; 270(270): 192-6.
[http://dx.doi.org/10.1016/j.ijcard.2018.06.006] [PMID: 29903517]
[9]
Dorbala S, Ando Y, Bokhari S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization. J Card Fail 2019; 25(11): 854-65.
[http://dx.doi.org/10.1016/j.cardfail.2019.08.002] [PMID: 31473267]
[10]
Castano A, Haq M, Narotsky DL, et al. Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 2016; 1(8): 880-9.
[http://dx.doi.org/10.1001/jamacardio.2016.2839] [PMID: 27557400]
[11]
Hutt DF, Fontana M, Burniston M, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging 2017; 18(12): 1344-50.
[http://dx.doi.org/10.1093/ehjci/jew325] [PMID: 28159995]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy